Bright Minds Biosciences Inc (DRUG) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · United States · ISIN CA10919W4056

Price
32.76 USD
Market cap
323.12 m USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-14.91 %
Return on assets (ROA)
-14.49 %

Bright Minds Biosciences Inc financials

Fiscal year20242025
Revenue0.00 CAD0.00 CAD
Gross profit–-76,976.00 CAD
Operating income-2.82 m CAD-13.94 m CAD
EBIT-2.80 m CAD-12.23 m CAD
Net income-2.80 m CAD-12.23 m CAD
Diluted EPS – continuing operations-0.65 CAD-1.78 CAD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Bright Minds Biosciences Inc

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.